查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1229676

亚斯伯格症候群的全球市场:至2030年的预测

Asperger Syndrome Market Research Report Forecast Till 2030
出版日期: | 出版商: Market Research Future | 英文 100 Pages | 商品交期: 请询问到货日

价格

全球亚斯伯格症候群的市场规模，预计至2030年的调查期间中以3.70％的年复合成长率成长。由于精神药理学的进步，可用目标药物疗法进行，因此，更好的药物治疗的可用性推动市场的成长。

本报告提供全球亚斯伯格症候群市场相关调查分析，市场动态，市场分析，竞争情形，企业简介等系统性资讯。

目录

第1章 报告开端

第2章 市场简介

  • 定义
  • 调查范围
    • 调查目的
    • 假设
    • 限制事项

第3章 调查手法

  • 简介
  • 1次调查
  • 2次调查
  • 市场规模的估计

第4章 市场动态

  • 促进因素
  • 阻碍因素
  • 机会
  • 课题
  • 宏观经济指标
  • 技术趋势与评估

第5章 市场要素分析

  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 新加入业者的威胁
    • 替代品的威胁
    • 竞争的激烈程度
  • 价值链分析
  • 投资可行性分析
  • 价格分析

第6章 全球亚斯伯格症候群市场:各诊断

  • 简介
  • DSM-IV
  • 鑑别诊断
  • 儿童亚斯伯格症候群检验
  • GILLIAM亚斯伯格症量表(GADS)
  • KRUG亚斯伯格症指数(KADI)
  • 其他

第7章 全球亚斯伯格症候群市场:各治疗

  • 简介
  • 父母的教育和培训
  • 社群技术训练
  • 语言疗法
  • 应用行为分析(ABA)
  • 投药

第8章 全球亚斯伯格症候群市场:各终端用户

  • 简介
  • 医院
  • 诊所
  • 诊断中心
  • 药妆店
  • 药局
  • 其他

第9章 全球亚斯伯格症候群市场:各地区

  • 简介
  • 南北美洲
    • 北美
    • 南美
  • 欧洲
    • 西欧
    • 东欧
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 大韩民国
    • 其他的亚太地区
  • 中东和非洲
    • 阿拉伯联合大公国
    • 沙乌地阿拉伯
    • 阿曼
    • 科威特
    • 卡达
    • 其他的中东及非洲

第10章 企业形势

  • 简介
  • 市场占有率分析
  • 主要的开发与策略
    • 主要的开发

第11章 企业简介

  • ELI LILLY AND COMPANY'S
  • SHIRE
  • JAZZ PHARMACEUTICALS
  • PFIZER
  • GLAXOSMITHKLINE
  • FOREST LABORATORIES, INC.
  • JOHNSON & JOHNSON SERVICES, INC.
  • 其他

第12章 MRFR的结论

  • 主要调查结果
    • 从CEO的观点
    • 未满足需求
  • 值得注意的主要企业
  • 亚斯伯格症候群产业的预测

第13章 附录

Product Code: MRFR/Pharma/4383-HCR

Market Overview

The Asperger Syndrome market should enlist a CAGR of 3.70% during the forecast time period. Asperger's syndrome is furthermore called Intellectually lopsided Reach Issue which generally begins in youthfulness and continues to stay till death. There are several vital differentiations not entirely set in stone to have a chemical imbalance and those with Asperger's syndrome. A couple of clinical specialists have acknowledged that Asperger's syndrome is a milder type of chemical imbalance. Overall, the secondary effects showed up in Asperger's syndrome are milder; in any case, the children not set in stone to have a chemical imbalance range tangle.

The rising regularity of the chemical imbalance and the extensive variety of the condition are the fundamental clarifications behind the overall advancement of the Asperger syndrome industry. Lately, World Prosperity Affiliation has communicated that there were around 1 of each not set in stone to have a mental imbalance. Progressing assessments show that there are a couple of explanations behind the syndrome, for instance, unforeseen work, a youth brought into the world not long after its kinfolk, family heritage, more prepared gatekeepers, any mental issue, epilepsy, or malignant growth in the psyche. A rising number of purposes behind the condition and normal components have expanded the overall Asperger syndrome marked improvement of late.

The degrees of progress in Psychopharmacology concerning arranging their medications to target unequivocal patients and having less delayed consequences yet more suitable have expanded the overall advancement of the Asperger Syndrome industry recently. While there are still many cases where the necessary medication is not supplied, the increased frequency of chemical imbalance range mix and Asperger syndrome is having a significant impact on the recent growth of the Asperger syndrome market.

Market Segmentation

Asperger Syndrome, Pervasive Developmental Disorder, Autistic Disorder, and Disintegrative Disorder are the several types of disorders that make up the market.

The market is divided into four categories based on deployment: Applied Behavior Analysis (ABA), Speech and Language Therapy, and Occupation Therapy.

Drug Treatments, Antipsychotic Medications, SSRIs, Stimulants, and Sleep Medicine are all included in the Treatment part.

Regional Analysis

America is likely to lead the Asperger Syndrome industry. Over 3.5 million Americans are living with the condition as per a new report. In no less than 10 years, a few locales in America exhibits more than a 119.4% increment concerning the number of cases. The costs brought about in treating the condition have expanded by over USD 236-262 billion lately. Such factors have expanded the general development of the Asperger Syndrome industry.

The administrative drives and presence of driving market players in Europe are the essential purposes behind the development of the Asperger Syndrome industry in Europe. Ease in the repayment approaches and propelling foundation of the medical services places are reinforcing the development of the Asperger Syndrome industry.

Major Players

Asperger Syndrome Market Competitors are Eli Lilly and Company, Shire, Jazz Pharmaceuticals, Pfizer, GlaxoSmithKline, Forest Laboratories, Johnson & Johnson, Bristol-Myers Squibb, Otsuka pharmaceutical, and AstraZeneca.

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

TABLE OF CONTENTS:

CHAPTER 1. REPORT PROLOGUE

CHAPTER 2. MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
    • 2.2.1 RESEARCH OBJECTIVE
    • 2.2.2 ASSUMPTIONS
    • 2.2.3 LIMITATIONS

CHAPTER 3. RESEARCH METHODOLOGY

  • 3.1 INTRODUCTION
  • 3.2 PRIMARY RESEARCH
  • 3.3 SECONDARY RESEARCH
  • 3.4 MARKET SIZE ESTIMATION

CHAPTER 4. MARKET DYNAMICS

  • 4.1 DRIVERS
  • 4.2 RESTRAINTS
  • 4.3 OPPORTUNITIES
  • 4.4 CHALLENGES
  • 4.5 MACROECONOMIC INDICATORS
  • 4.6 TECHNOLOGY TRENDS & ASSESSMENT

CHAPTER 5. MARKET FACTOR ANALYSIS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 BARGAINING POWER OF SUPPLIERS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 THREAT OF NEW ENTRANTS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF RIVALRY
  • 5.2 VALUE CHAIN ANALYSIS
  • 5.3 INVESTMENT FEASIBILITY ANALYSIS
  • 5.4 PRICING ANALYSIS

CHAPTER 6. GLOBAL ASPERGER SYNDROME MARKET, BY DIAGNOSIS

  • 6.1 INTRODUCTION
  • 6.2 DSM-IV
    • 6.2.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 6.3 DIFFERENTIAL DIAGNOSIS
    • 6.3.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 6.4 CHILDHOOD ASPERGER SYNDROME TEST
    • 6.4.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 6.5 GILLIAM ASPERGER'S DISORDER SCALE (GADS)
    • 6.5.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 6.6 KRUG ASPERGER'S DISORDER INDEX (KADI)
    • 6.6.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 6.7 OTHERS
    • 6.7.1 MARKET ESTIMATES & FORECAST, 2022-2030

CHAPTER 7. GLOBAL ASPERGER SYNDROME MARKET, BY TREATMENT

  • 7.1 INTRODUCTION
  • 7.2 PARENT EDUCATION & TRAINING
    • 7.2.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 7.3 SOCIAL SKILLS TRAINING
    • 7.3.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 7.4 SPEECH-LANGUAGE THERAPY
    • 7.4.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 7.5 APPLIED BEHAVIORAL ANALYSIS (ABA)
    • 7.5.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 7.6 MEDICATION
    • 7.6.1 MARKET ESTIMATES & FORECAST, 2022-2030

CHAPTER 8. GLOBAL ASPERGER SYNDROME MARKET, BY END-USER

  • 8.1 INTRODUCTION
  • 8.2 HOSPITALS
    • 8.2.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 8.3 CLINICS
    • 8.3.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 8.4 DIAGNOSTIC CENTERS
    • 8.4.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 8.5 DRUG STORES
    • 8.5.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 8.6 PHARMACIES
    • 8.6.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 8.7 OTHERS
    • 8.7.1 MARKET ESTIMATES & FORECAST, 2022-2030

CHAPTER 9. GLOBAL ASPERGER SYNDROME MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 AMERICAS
    • 9.2.1 NORTH AMERICA
      • 9.2.1.1 U.S.
      • 9.2.1.1 CANADA
    • 9.2.2 SOUTH AMERICA
  • 9.3 EUROPE
    • 9.3.1 WESTERN EUROPE
      • 9.3.1.1 GERMANY
      • 9.3.1.2 FRANCE
      • 9.3.1.3 ITALY
      • 9.3.1.4 SPAIN
      • 9.3.1.5 U.K.
      • 9.3.1.6 REST OF WESTERN EUROPE
    • 9.3.2 EASTERN EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 JAPAN
    • 9.4.2 CHINA
    • 9.4.3 INDIA
    • 9.4.4 AUSTRALIA
    • 9.4.5 REPUBLIC OF KOREA
    • 9.4.6 REST OF ASIA PACIFIC
  • 9.5 THE MIDDLE EAST & AFRICA
    • 9.5.1 UNITED ARAB EMIRATES
    • 9.5.2 SAUDI ARABIA
    • 9.5.3 OMAN
    • 9.5.4 KUWAIT
    • 9.5.5 QATAR
    • 9.5.6 REST OF THE MIDDLE EAST & AFRICA

CHAPTER 10 COMPANY LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 MARKET SHARE ANALYSIS
  • 10.3 KEY DEVELOPMENT & STRATEGIES
    • 10.3.1 KEY DEVELOPMENTS

CHAPTER 11 COMPANY PROFILES

  • 11.1 ELI LILLY AND COMPANY'S
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 TYPES OVERVIEW
    • 11.1.3 FINANCIALS
    • 11.1.4 SWOT ANALYSIS
  • 11.2 SHIRE
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 TYPES OVERVIEW
    • 11.2.3 FINANCIAL OVERVIEW
    • 11.2.4 KEY DEVELOPMENTS
    • 11.2.5 SWOT ANALYSIS
  • 11.3 JAZZ PHARMACEUTICALS
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 TYPES OVERVIEW
    • 11.3.3 FINANCIAL OVERVIEW
    • 11.3.4 KEY DEVELOPMENT
    • 11.3.5 SWOT ANALYSIS
  • 11.4 PFIZER
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 TYPES/BUSINESS SEGMENT OVERVIEW
    • 11.4.3 FINANCIAL OVERVIEW
    • 11.4.4 KEY DEVELOPMENT
    • 11.4.5 SWOT ANALYSIS
  • 11.5 GLAXOSMITHKLINE
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 TYPES OVERVIEW
    • 11.5.3 FINANCIAL OVERVIEW
    • 11.5.4 KEY DEVELOPMENTS
  • 11.6 FOREST LABORATORIES, INC.
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 TYPES OVERVIEW
    • 11.6.3 FINANCIAL OVERVIEW
    • 11.6.4 KEY DEVELOPMENTS
  • 11.7 JOHNSON & JOHNSON SERVICES, INC.
    • 11.7.1 OVERVIEW
    • 11.7.2 TYPES OVERVIEW
    • 11.7.3 FINANCIALS
    • 11.7.4 KEY DEVELOPMENTS
    • 11.7.5 SWOT ANALYSIS
  • 11.8 OTHERS

CHAPTER 12 MRFR CONCLUSION

  • 12.1 KEY FINDINGS
    • 12.1.1 FROM CEO'S VIEW POINT
    • 12.1.2 UNMET NEEDS OF THE MARKET
  • 12.2 KEY COMPANIES TO WATCH
  • 12.3 PREDICTION OF ASPERGER SYNDROME INDUSTRY

CHAPTER 13 APPENDIX

LIST OF TABLES

  • TABLE 1 ASPERGER SYNDROME INDUSTRY SYNOPSIS, 2022-2030
  • TABLE 2 ASPERGER SYNDROME MARKET ESTIMATES & FORECAST, 2022-2030, (USD MILLION)
  • TABLE 3 ASPERGER SYNDROME MARKET, BY REGION, 2022-2030, (USD MILLION)
  • TABLE 4 ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 5 ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 6 ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 7 NORTH AMERICA ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 8 NORTH AMERICA ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 9 NORTH AMERICA ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 10 U.S. ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 11 U.S. ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 12 U.S. ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 13 CANADA ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 14 CANADA ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 15 CANADA ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 16 SOUTH AMERICA ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 17 SOUTH AMERICA ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 18 SOUTH AMERICA ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 19 EUROPE ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 20 EUROPE ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 21 EUROPE ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 22 WESTERN EUROPE ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 23 WESTERN EUROPE ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 24 WESTERN EUROPE ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 25 EASTERN EUROPE ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 26 EASTERN EUROPE ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 27 EASTERN EUROPE ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 28 ASIA PACIFIC ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 29 ASIA PACIFIC ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 30 ASIA PACIFIC ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 31 THE MIDDLE EAST & AFRICA ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 32 THE MIDDLE EAST & AFRICA ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 33 THE MIDDLE EAST & AFRICA ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 RESEARCH PROCESS
  • FIGURE 2 SEGMENTATION FOR THE ASPERGER SYNDROME MARKET
  • FIGURE 3 SEGMENTATION MARKET DYNAMICS FOR THE ASPERGER SYNDROME MARKET
  • FIGURE 4 GLOBAL ASPERGER SYNDROME MARKET SHARE, BY DIAGNOSIS, 2022
  • FIGURE 5 GLOBAL ASPERGER SYNDROME MARKET SHARE, BY TREATMENT, 2022
  • FIGURE 6 GLOBAL ASPERGER SYNDROME MARKET SHARE, BY END-USER, 2022
  • FIGURE 7 GLOBAL ASPERGER SYNDROME MARKET SHARE, BY REGION, 2022
  • FIGURE 8 NORTH AMERICA ASPERGER SYNDROME MARKET SHARE, BY COUNTRY, 2022
  • FIGURE 9 EUROPE ASPERGER SYNDROME MARKET SHARE, BY COUNTRY, 2022
  • FIGURE 10 ASIA PACIFIC ASPERGER SYNDROME MARKET SHARE, BY COUNTRY, 2022
  • FIGURE 11 MIDDLE EAST & AFRICA ASPERGER SYNDROME MARKET SHARE, BY COUNTRY, 2022
  • FIGURE 12 GLOBAL ASPERGER SYNDROME MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
  • FIGURE 13 ELI LILLY AND COMPANY'S: KEY FINANCIALS
  • FIGURE 14 ELI LILLY AND COMPANY'S: SEGMENTAL REVENUE
  • FIGURE 15 ELI LILLY AND COMPANY'S: GEOGRAPHICAL REVENUE
  • FIGURE 16 SHIRE: KEY FINANCIALS
  • FIGURE 17 SHIRE: SEGMENTAL REVENUE
  • FIGURE 18 SHIRE: GEOGRAPHICAL REVENUE
  • FIGURE 19 JAZZ PHARMACEUTICALS: KEY FINANCIALS
  • FIGURE 20 JAZZ PHARMACEUTICALS: SEGMENTAL REVENUE
  • FIGURE 21 JAZZ PHARMACEUTICALS: GEOGRAPHICAL REVENUE
  • FIGURE 22 PFIZER: KEY FINANCIALS
  • FIGURE 23 PFIZER: SEGMENTAL REVENUE
  • FIGURE 24 PFIZER: GEOGRAPHICAL REVENUE
  • FIGURE 25 GLAXOSMITHKLINE: KEY FINANCIALS
  • FIGURE 26 GLAXOSMITHKLINE: SEGMENTAL REVENUE
  • FIGURE 27 GLAXOSMITHKLINE GEOGRAPHICAL REVENUE
  • FIGURE 28 FOREST LABORATORIES, INC.: KEY FINANCIALS
  • FIGURE 29 FOREST LABORATORIES, INC.: SEGMENTAL REVENUE
  • FIGURE 30 FOREST LABORATORIES, INC.: GEOGRAPHICAL REVENUE
  • FIGURE 31 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS
  • FIGURE 32 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE
  • FIGURE 33 JOHNSON & JOHNSON SERVICES, INC.: GEOGRAPHICAL REVENUE